Edition:
United Kingdom

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

2.00USD
22 Jun 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.00
Open
$1.99
Day's High
$2.05
Day's Low
$1.99
Volume
6,545
Avg. Vol
16,685
52-wk High
$11.90
52-wk Low
$1.71

Chart for

About

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal... (more)

Overall

Beta: -8.40
Market Cap(Mil.): $71.13
Shares Outstanding(Mil.): 0.12
Dividend: --
Yield (%): --

Financials

  AKTX.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -1.84 -- --
ROI: -68.01 2.00 14.38
ROE: -68.13 3.49 16.08

BRIEF-David Horn Solomon Resigns As CEO Of Akari Therapeutics

* AKARI THERAPEUTICS SAYS ON MAY 8, DAVID HORN SOLOMON, RESIGNED AS CEO AND AS A MEMBER OF BOARD EFFECTIVE IMMEDIATELY - SEC FILING

11 May 2018

BRIEF-Akari Therapeutics Qtrly Loss Per Common Share $0.01

* AKARI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS

21 Mar 2018

Earnings vs. Estimates